A 2025 meta-analysis in non–small-cell lung cancer (NSCLC) indicates glucocorticoid administration is significantly associated with worse progression-free survival (PFS) and overall survival (OS) for patients on ICIs
wasrpublication.com/index.php/wjams/article/v...Posted Dec 1, 2025, 4:08 AM UTC
20